Dosing chart / Healing & recovery

TB-500 dosage

Also known as: thymosin beta-4 fragment

What is TB-500?

TB-500 is a lab-made peptide of seven amino acids, copied from a short stretch of thymosin beta-4, a 43-amino-acid protein found widely in human tissues. Chemists examining it as a suspected doping product identified its structure in 2012. TB-500 is a trade name, not an official drug name.

How it works

The parent protein, thymosin beta-4, interacts with actin (a building block of the cell skeleton) and in animal studies is linked to new blood vessel growth and reduced inflammation. Whether the TB-500 fragment does the same is unproven: in one cell study TB-500 itself did not speed wound closure, while one of its breakdown products did.

What the evidence shows

There are no human studies of TB-500. FDA reviewers searched the medical literature in 2026 and found no clinical trials, no record of it being given to patients for any condition and no animal toxicity studies. Human trials exist only for full-length thymosin beta-4, a different and larger molecule: early studies in healthy volunteers reported no serious adverse events, and a 72-person phase 2 dry-eye trial of eye drops missed both main endpoints while improving some secondary measures. Those results cannot be assumed to apply to the fragment, so its effectiveness and safety in people are unknown.

Reported side effects

  • No human safety data exist for TB-500; its side effects are unknown
  • Skin and gum darkening was reported to FDA by one person using a combined BPC-157 and TB-500 product
  • No animal toxicity studies were found by FDA reviewers

Cautions

  • FDA says injected peptides such as TB-500 may trigger unwanted immune reactions, made more likely by clumping and impurities.
  • A lab analysis of TB-500 products sold online found the contents did not consistently match the description.
  • FDA has found different salts, derivatives and active substances sold as TB-500, so a vial may not contain what the buyer expects.
  • Research on full thymosin beta-4 should not be read as evidence for TB-500.

Legal and regulatory status

TB-500 is not FDA-approved and is not part of any FDA-approved drug. FDA lists it among compounding substances that may present significant safety risks. In July 2026 an FDA advisory committee voted to recommend allowing pharmacy compounding, against the proposal of FDA's own reviewers; as of October 2026 FDA had not acted on that vote. The WADA Prohibited List bans thymosin beta-4 and its derivatives, naming TB-500, at all times under section S2.

Common questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a natural 43-amino-acid protein, while TB-500 is a synthetic seven-amino-acid piece of it. The human trials that exist used the full protein, not the fragment.

Has TB-500 been tested in humans?

Not in any published clinical study. FDA reviewers found no human data on TB-500 by any route, so both its benefits and its risks in people are unknown.

Is TB-500 legal for athletes?

No. It is named on the WADA Prohibited List under S2 (peptide hormones, growth factors and related substances), banned in and out of competition.

Sources

  1. FDA: Evaluation of TB-500 for the Pharmacy Compounding Advisory Committee, July 2026
  2. FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
  3. FDA: PCAC briefing document introduction, July 23-24, 2026
  4. Mintz: FDA's advisory committee votes on peptides, what it does and does not change
  5. Drug Testing and Analysis (PubMed abstract): Synthesis and characterization of the thymosin beta-4 fragment identified in TB-500 (2012)
  6. Journal of Chromatography B (PubMed abstract): TB-500 and its metabolites, wound healing activity in vitro (2024)
  7. Drug Testing and Analysis (PubMed abstract): TB500/TB1000 and SGF1000, misbranded and adulterated drugs (2023)
  8. Frontiers in Endocrinology: Progress on the Function and Application of Thymosin beta-4 (2021)
  9. Clinical Ophthalmology (PubMed abstract): Thymosin beta 4 ophthalmic solution for dry eye, phase 2 trial (2015)
  10. FDA: Evaluation of BPC-157 for the Pharmacy Compounding Advisory Committee, July 2026
  11. WADA: 2026 Prohibited List (copy hosted by the Czech National Sports Agency)

TB-500 reviews and Q&A

TopicRepliesLast activity

No reviews or questions yet. Be the first.

More in Healing & recovery

Stacks that include TB-500

Compare TB-500

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.